Identification of the risk factors associated with hypocalcemia induced by denosumab.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Biological and Pharmaceutical Bulletin

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1248/BPB.B13-00496PMID 23934346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?

  2013cited by this paper
• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

  2012cited by this paper
• Management of bone metastases in refractory prostate cancer – role of denosumab

  2012cited by this paper
• Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer.

  2012cited by this paper
• Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients

  2012cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  2011cited by this paper
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

  2009cited by this paper
• RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

  2008cited by this paper
• Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

  2008cited by this paper
• [Transport of minerals in renal tubules and its hormonal regulation].

  2007cited by this paper
• Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

  2006cited by this paper
• Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

  2005cited by this paper
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

  2005cited by this paper
• Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

  2003cited by this paper
• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  2002cited by this paper
• Skeletal complications of malignancy

  1997cited by this paper
• Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH.

  1995cited by this paper
• Prediction of creatinine clearance from serum creatinine in spinal cord injury patients

  1983cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Severe denosumab-induced hypocalcemia requiring long-term intensified medication in a patient with EGFR-mutant lung cancer and diffuse osteoblastic bone metastases

  2025cites this paper
• Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab

  2025cites this paper
• Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single‐center cohorts study

  2024cites this paper
• Denosumab-Induced Recurrent Severe Hypocalcaemia in a Patient With Chronic Kidney Disease: A Case Report

  2024cites this paper
• The use of denosumab in osteoporosis – an update on efficacy and drug safety

  2024cites this paper
• External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative Database

  2024cites this paper
• Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report

  2023cites this paper
• Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D3.

  2023cites this paper
• Electrolytes disturbances in cancer patients

  2022cites this paper
• Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D3)/Calcium Supplement

  2022cites this paper
• Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report

  2021cites this paper
• Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.

  2021cites this paper
• Fractures in patients with chronic kidney disease

  2021cites this paper
• Drug-induced hypocalcemia

  2021cites this paper
• Factors determining the efficacy of recombinant human thrombomodulin in the treatment of sepsis-induced disseminated intravascular coagulation.

  2021cites this paper
• Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective

  2020cites this paper
• The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn

  2020cites this paper
• Denosumab-associated hypocalcemia: Does gender play a role?

  2020cites this paper
• A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study

  2020cites this paper
• Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents.

  2020cites this paper
• Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?

  2019cites this paper
• Correlation between high serum alkaline phosphatase levels and denosumab‐related hypocalcemia in patients with multiple myeloma

  2019cites this paper
• Identification of risk factors and development of detection algorithm for denosumab‐induced hypocalcaemia

  2018cites this paper
• A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and αvβ3 integrin for osteoporosis therapy

  2018cites this paper
• Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency

  2018cites this paper
• Bone health in chronic kidney disease‐mineral and bone disorder: a clinical case seminar and update

  2018cites this paper
• Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review

  2018cites this paper
• Recent Update on RANKL Inhibitor

  2018cites this paper
• Theranostic of biopharmaceuticals

  2017cites this paper
• Denosumab for the treatment of osteoporosis

  2017cites this paper
• Denosumab treatment in patients with different courses of osteoporosis

  2017cites this paper
• Denosumab: Renal Safety Evaluation

  2017cites this paper
• Hypocalcemia after Denosumab in a Pulmonary Hypertension Patient Receiving Epoprostenol

  2017cites this paper
• Effect of the Proton Pump Inhibitors on the Development of Hypocalcemia Induced by Denosumab

  2017cites this paper
• Dramatic Elevation in Parathyroid Hormone after Denosumab Administration in a Woman with Scleroderma

  2017cites this paper
• Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients

  2017cites this paper
• Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment

  2017cites this paper
• Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures

  2017cites this paper
• Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis

  2017cites this paper
• Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis

  2017cites this paper
• Examens préthérapeutiques et surveillance des traitements par biomédicaments

  2017cites this paper
• High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis

  2016influential citation
• Risk Factors for Hypocalcemia following Treatment with Denosumab inPatients with Bone Metastases from Prostate Cancer

  2016cites this paper
• Chronic kidney disease and fragility fracture

  2016cites this paper
• Other Safety Concerns

  2016cites this paper
• Denosumab‐associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting

  2016cites this paper
• High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.

  2016cites this paper
• Severe Refractory Hypocalcemia in a Patient with Metastatic Prostate Carcinoma Following Denosumab Injection

  2016cites this paper
• Multiple Factors in Recurrent Symptomatic Hypocalcemia Following Denosumab in a Patient Receiving Home Parenteral Nutrition.

  2016cites this paper
• Pharmacoepidemiologic Investigation of the Risk Factors Associated with Hypocalcemia Induced by Denosumab

  2015cites this paper
• Organic anxiety in a woman with breast cancer receiving denosumab.

  2015influential citation
• MANAGEMENT OF FRAGILITY FRACTURE IN CHRONIC KIDNEY DISEASE

  2015cites this paper
• New insights into treatment of osteoporosis in postmenopausal women

  2015cites this paper
• New management options for osteoporosis with emphasis on SERMs

  2015cites this paper
• Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys

  2015cites this paper
• Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency

  2015cites this paper
• How to predict and treat increased fracture risk in chronic kidney disease

  2015cites this paper
• The Influence of Polypharmacy on Nutrition

  2015cites this paper
• [Hypocalcemia with encephalopathy and epileptic seizures secondary to treatment with denosumab].

  2015cites this paper
• Acute Medical Aspects Related to Osteoporosis and Its Therapy

  2014cites this paper
• Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer

  2014cites this paper
• Denosumab in osteoporosis

  2014cites this paper
• Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?

  2014cites this paper